Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1962 1
1963 2
1964 1
1990 1
1999 1
2008 1
2013 1
2014 5
2015 2
2016 1
2017 4
2018 2
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Resolution of organ dysfunction as a predictor of long-term survival in necrotizing soft tissue infections: Analysis of the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections trial and a retrospective claims database-linked chart study.
Brakenridge SC, Wilfret DA, Maislin G, Andrade KE, Walker V, May AK, Dankner WM, Bulger EM. Brakenridge SC, et al. J Trauma Acute Care Surg. 2021 Aug 1;91(2):384-392. doi: 10.1097/TA.0000000000003183. J Trauma Acute Care Surg. 2021. PMID: 33797490 Clinical Trial.
METHODS: We performed a combined analysis of NSTI patients from the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections randomized-controlled interventional trial (ATB-202) and comprehensive administrative database (ATB-204) to determine the assoc …
METHODS: We performed a combined analysis of NSTI patients from the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissu …
Acute kidney injury: emerging pharmacotherapies in current clinical trials.
Benoit SW, Devarajan P. Benoit SW, et al. Pediatr Nephrol. 2018 May;33(5):779-787. doi: 10.1007/s00467-017-3695-3. Epub 2017 Jun 10. Pediatr Nephrol. 2018. PMID: 28601936 Free PMC article. Review.
Categorized by their general mechanism of action, the therapies discussed include anti-inflammatory agents (recAP, AB103, ABT-719), antioxidants (iron chelators, heme arginate), vasodilators (levosimendan), apoptosis inhibitors (QPI-1002), and repair agents (THR-184, BB-3, …
Categorized by their general mechanism of action, the therapies discussed include anti-inflammatory agents (recAP, AB103, ABT-719), a …
Single administration of p2TA (AB103), a CD28 antagonist peptide, prevents inflammatory and thrombotic reactions and protects against gastrointestinal injury in total-body irradiated mice.
Mirzoeva S, Paunesku T, Wanzer MB, Shirvan A, Kaempfer R, Woloschak GE, Small W Jr. Mirzoeva S, et al. PLoS One. 2014 Jul 23;9(7):e101161. doi: 10.1371/journal.pone.0101161. eCollection 2014. PLoS One. 2014. PMID: 25054224 Free PMC article.
The goal of this study was to elucidate the action of the CD28 mimetic peptide p2TA (AB103) that attenuates an excessive inflammatory response in mitigating radiation-induced inflammatory injuries. ...
The goal of this study was to elucidate the action of the CD28 mimetic peptide p2TA (AB103) that attenuates an excessive inflammatory …
Recent early clinical drug development for acute kidney injury.
Gallagher KM, O'neill S, Harrison EM, Ross JA, Wigmore SJ, Hughes J. Gallagher KM, et al. Expert Opin Investig Drugs. 2017 Feb;26(2):141-154. doi: 10.1080/13543784.2017.1274730. Epub 2016 Dec 27. Expert Opin Investig Drugs. 2017. PMID: 27997816 Review.
Agents covered include- QPI-1002, THR-184, BB-3, heme arginate, human recombinant alkaline phosphatase (recAP), ciclosporin A, AB103, levosimendan, AC607 and ABT-719. Expert opinion: Due to the heterogenous nature of AKI, agents with the widest pleiotropic effects on multi …
Agents covered include- QPI-1002, THR-184, BB-3, heme arginate, human recombinant alkaline phosphatase (recAP), ciclosporin A, AB103, …
Interventions for necrotizing soft tissue infections in adults.
Hua C, Bosc R, Sbidian E, De Prost N, Hughes C, Jabre P, Chosidow O, Le Cleach L. Hua C, et al. Cochrane Database Syst Rev. 2018 May 31;5(5):CD011680. doi: 10.1002/14651858.CD011680.pub2. Cochrane Database Syst Rev. 2018. PMID: 29851032 Free PMC article. Review.
We are uncertain of the effects of these treatments on mortality within 30 days (risk ratio (RR) 3.00, 95% confidence interval (CI) 0.39 to 23.07) and serious adverse events at 28 days (RR 0.63, 95% CI 0.30 to 1.31) because the quality of the evidence is very low.AB103 ver …
We are uncertain of the effects of these treatments on mortality within 30 days (risk ratio (RR) 3.00, 95% confidence interval (CI) 0.39 to …
A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.
Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldawer LL, Demetriades D, Talving P, Schreiber M, Ham B, Cohen M, Opal S, Segalovich I, Maislin G, Kaempfer R, Shirvan A. Bulger EM, et al. JAMA Surg. 2014 Jun;149(6):528-36. doi: 10.1001/jamasurg.2013.4841. JAMA Surg. 2014. PMID: 24740134 Clinical Trial.
IMPORTANCE: Necrotizing soft-tissue infections (NSTI) have high morbidity and mortality rates despite aggressive surgical debridement and antibiotic therapy. AB103 is a peptide mimetic of the T-lymphocyte receptor, CD28. We hypothesized that AB103 will limit inflamm …
IMPORTANCE: Necrotizing soft-tissue infections (NSTI) have high morbidity and mortality rates despite aggressive surgical debridement and an …
CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis.
Ramachandran G, Kaempfer R, Chung CS, Shirvan A, Chahin AB, Palardy JE, Parejo NA, Chen Y, Whitford M, Arad G, Hillman D, Shemesh R, Blackwelder W, Ayala A, Cross AS, Opal SM. Ramachandran G, et al. J Infect Dis. 2015 Mar 15;211(6):995-1003. doi: 10.1093/infdis/jiu556. Epub 2014 Oct 9. J Infect Dis. 2015. PMID: 25305323 Free PMC article.
METHODS: Mice received AB103, followed by an injection of Escherichia coli 0111:B4 lipopolysaccharide (LPS); underwent induction E. coli 018:K1 peritonitis induction, followed by treatment with AB103; or underwent cecal ligation and puncture (CLP), followed by treat …
METHODS: Mice received AB103, followed by an injection of Escherichia coli 0111:B4 lipopolysaccharide (LPS); underwent induction E. c …
Pyrrole-Based Macrocyclic Small-Molecule Inhibitors That Target Oocyte Maturation.
Gunasekaran P, Lee SR, Jeong SM, Kwon JW, Takei T, Asahina Y, Bang G, Kim S, Ahn M, Ryu EK, Kim HN, Nam KY, Shin SY, Hojo H, Namgoong S, Kim NH, Bang JK. Gunasekaran P, et al. ChemMedChem. 2017 Apr 20;12(8):580-589. doi: 10.1002/cmdc.201700048. Epub 2017 Mar 28. ChemMedChem. 2017. PMID: 28296169
Polo-like kinase 1 (PLK1) plays crucial roles in various stages of oocyte maturation. Recently, we reported that the peptidomimetic compound AB103-8, which targets the polo box domain (PBD) of PLK1, affects oocyte meiotic maturation and the resumption of meiosis. ...
Polo-like kinase 1 (PLK1) plays crucial roles in various stages of oocyte maturation. Recently, we reported that the peptidomimetic compound …
A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes.
Ramachandran G, Tulapurkar ME, Harris KM, Arad G, Shirvan A, Shemesh R, Detolla LJ, Benazzi C, Opal SM, Kaempfer R, Cross AS. Ramachandran G, et al. J Infect Dis. 2013 Jun 15;207(12):1869-77. doi: 10.1093/infdis/jit104. Epub 2013 Mar 14. J Infect Dis. 2013. PMID: 23493729 Free PMC article.
Administration of a single dose of AB103 increased survival when given up to 5 hours after infection, reduced inflammatory cytokine expression and bacterial burden at the site of infection, and improved muscle inflammation in a dose-dependent manner, without compromising c …
Administration of a single dose of AB103 increased survival when given up to 5 hours after infection, reduced inflammatory cytokine e …
Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections.
Bulger EM, May A, Dankner W, Maislin G, Robinson B, Shirvan A. Bulger EM, et al. J Trauma Acute Care Surg. 2017 Oct;83(4):622-627. doi: 10.1097/TA.0000000000001564. J Trauma Acute Care Surg. 2017. PMID: 28538644 Clinical Trial.
Several data sets were used to assess validity: (i) a retrospective data set of 198 patients treated during 2013 at 12 US trauma centers; (ii) a subset with high disease acuity, admission mSOFA score of 3 or higher (n = 69); and (iii) 40 patients from a multicenter, phase 2 rando …
Several data sets were used to assess validity: (i) a retrospective data set of 198 patients treated during 2013 at 12 US trauma centers; (i …
22 results